Two Sigma Securities LLC Invests $630,000 in Illumina, Inc. (NASDAQ:ILMN)

Two Sigma Securities LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,717 shares of the life sciences company’s stock, valued at approximately $630,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Golden State Wealth Management LLC acquired a new position in shares of Illumina in the 4th quarter worth approximately $32,000. Versant Capital Management Inc boosted its holdings in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Illumina in the fourth quarter worth $45,000. Assetmark Inc. increased its stake in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares during the last quarter. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of Illumina during the fourth quarter worth $48,000. 89.42% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ILMN shares. Morgan Stanley lowered their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 11th. Citigroup dropped their price target on Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a research report on Monday, April 7th. Guggenheim reduced their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Canaccord Genuity Group dropped their target price on Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, March 11th. Finally, Robert W. Baird reduced their price target on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $138.70.

Illumina Stock Performance

Shares of ILMN opened at $77.35 on Friday. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The stock has a market capitalization of $12.24 billion, a P/E ratio of -10.07, a P/E/G ratio of 1.60 and a beta of 1.38. The firm’s 50 day moving average is $82.02 and its 200-day moving average is $118.20. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.